Anika Therapeutics, Inc. (ANIK) Misses Q1 EPS by 3c

Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q1 EPS of $0.14, $0.03 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $14.4 million versus the consensus estimate of $18.2 million.

For earnings history and earnings-related data on Anika Therapeutics, Inc. (ANIK) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Mannatech (MTEX) Tops Q2 EPS by 53c
• Aptera Motors (SEV) Reports Q2 Loss of $0.20